Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most
advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown …

Systemic combination chemotherapy and intrathecal chemotherapy markedly increased the
survival rate of children with ALL. In the past two decades, the use of minimal (measurable) …

T cell acute lymphoblastic leukemia (T-ALL) is difficult to treat when it relapses after therapy
or is chemoresistant; the prognosis of patients with relapsed or refractory T-ALL is generally …

Chimeric antigen receptor T (CAR‐T) therapy has emerged as a revolutionary new pillar in
cancer care, particularly in relapsed/refractory (r/r) B‐cell malignancies. Following …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …

Cure rates for acute lymphoblastic leukemia (ALL), the most common childhood cancer have
steadily improved over the past five decades. This is due to intensifying systemic therapy …

Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at
least a third of those diagnosed still will require second or further lines for relapsed or …

Background Tisagenlecleucel was approved by the Food and Drug Administration (FDA) in
2017 for refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-ALL in≥ 2nd relapse …